Aptiv Solution announced it has acquired SRA Global Clinical Development (GCD), the CRO division of SRA International, Inc. based in Durham, N.C., with offices in Paris, France and Milton Park, England.
SRA GCD and its predecessor companies have built a substantial business by delivering high-quality clinical trial and regulatory services around the globe. SRA GCD’s regulatory consulting team based near London adds significantly to the Aptiv Solutions regulatory services group. The additional talent from SRA GCD accelerates Aptiv Solutions leadership in regulatory services.
“We believe the GCD business, as a part of Aptiv Solutions, has greater opportunity to pursue a wider range of initiatives that align with its mission,” said SRA President and CEO Bill Ballhaus
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.